🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› EU
Clinical trial register · European Union · CTIS

Recently authorised EU trials

The most recently authorised trials on the EU Clinical Trials Information System (CTIS), the single register for every trial run under the EU Clinical Trials Regulation (536/2014). CTIS holds a far larger historical archive than any one list can usefully show — this register states both numbers rather than picking one.

Download CSV
Source: EMA Clinical Trials Information System (CTIS). Showing the 2500 most recently authorised of 12445 total CTIS records — a stated recency window, not the full historical archive. Synced 20 Sep 2026, 03:17 UTC
2500
Shown in this register
most recently authorised
12,445
Total on CTIS
full historical archive
745
Phase III
within the shown window
Top member states
Spain 1023 France 890 Germany 861 Italy 742 Poland 581 Netherlands 524
Narrow the registerReset
Phase
Phase I 558 Phase I/II 214 Phase II 726 Phase III 745 Phase IV 257
Lead sponsor
AstraZeneca AB 60 Assistance Publique Hopitaux De Paris 49 Merck Sharp & Dohme LLC 48 Pfizer Inc. 45 Novo Nordisk A/S 42 Clear sponsor filter
Member state
Spain 1023 France 890 Germany 861 Italy 742 Poland 581 Netherlands 524 Belgium 426 Czechia 327
All 28 states
17 of 2500 shown studies
Download
Phase
Study
Lead sponsor
Area
Member states
Decision
Phase II
DIRECTION- Discontinuation versus continuation of riociguat monotherapy in chronic thromboembolic pulmonary hypertension successfully treated with balloon pulmonary angioplasty
2026-525351-81-00chronic thromboembolic pulmonary hypertension
Assistance Publique Hopitaux De Paris
Cardiovascular Diseases
France
25/08/2026
Phase II
TIPS : Immunomodulatory Treatment of Interstitial Lung Disease Associated with Surfactant related Gene Mutations
2026-525336-41-00Interstitial Lung Disease
Assistance Publique Hopitaux De Paris
Respiratory Tract Diseases
France
14/08/2026
Phase II
SDH-FLUX - Development of a new biomarker for tumor development in patients with SDHx mutation by in vivo fluxomics
2023-506001-19-00paraganglioma or pheochromocytoma with surgical indication
Assistance Publique Hopitaux De Paris
Hormonal diseases
France
10/08/2026
Phase II
VIP-1 : Preclinical type 1 diabetes: the VIP-1 Study
2025-524318-27-00People with stage 1 or stage 2 T1D between the ages of 7 an…
Assistance Publique Hopitaux De Paris
Immune System Diseases
France
05/08/2026
Phase II
OBINUSS - Safety and efficacy of obinutuzumab in systemic sclerosis: a phase II, randomized, double-blinded versus placebo-controlled trial
2025-524003-68-00Patients with newly or active diffuse Systemic sclerosis at…
Assistance Publique Hopitaux De Paris
Immune System Diseases
France
28/07/2026
Phase II
Obinutuzumab for systemic lupus erythematosus pure membranous nephropathy: a phase II trial (OBLUMEN)
2024-519985-35-00systemic lupus erythematosus pure membranous nephropathy
Assistance Publique Hopitaux De Paris
Pathological Conditions, Signs and Symptoms
France
15/07/2026
Phase II
Shared decision-making in uncomplicated appendicitis: a pragmatic randomized trial comparing patient-driven choice (antibiotics only or appendectomy) with systematic appendectomy (FRENCH 47 — ALACARTE trial)
2025-520783-17-01Adult patients diagnosed with uncomplicated acute appendici…
Assistance Publique Hopitaux De Paris
Therapeutics
France
06/07/2026
Phase II
POMREP - Efficacy and safety of zoledronate versus placebo on pain at week 12 in pediatric patients with chronic recurrent multifocal osteomyelitis resistant to non-steroidal anti-inflammatory drug
2023-506420-93-00Chronic recurrent multifocal osteomyelitis (CRMO)
Assistance Publique Hopitaux De Paris
Musculoskeletal Diseases
France
26/05/2026
Phase II
Electrophysiological analysis of Gamma-Hydroxybutyrate-induced sleep in intensive care patients: A Pilot Double-Blind Randomized Controlled Trial.(GAMMA-SLEEP)
2025-521967-11-00The study population includes adult ICU patients with a hos…
Assistance Publique Hopitaux De Paris
Mental Disorders
France
28/04/2026
Phase II
A Phase 2, single arm Multicenter, Study testing Mezigdomide, Carfilzomib, and Dexamethasone (480Kd) in Participants with Relapsed or Refractory Multiple Myeloma (RRMM). (MEZI-KD)
2025-521090-14-00Patients with relapsed/refractory symptomatic multiple myel…
Assistance Publique Hopitaux De Paris
Hemic and Lymphatic Diseases
France
08/04/2026
Phase II
STARS - Prospective, bayesian, randomized, controlled, open-label, parallel-group, phase II interventional study evaluating efficacy and safety of secukinumab versus standard of care in active severe Takayasu patients
2024-516215-24-00TAkayasu ARteritiS
Assistance Publique Hopitaux De Paris
Immune System Diseases
France
26/02/2026
Phase II
BOOSTERS - BiOlogics in FOlliculitis decalvanS : an adaptaTivE tRial reSearch
2024-514848-88-00Folliculitis decalvans
Assistance Publique Hopitaux De Paris
Therapeutics
France
24/11/2025
Phase II
PALETTE - Adaptive platform trial for personalisation of sepsis treatment in children and adults: a multi-national, treatable traits-guided, adaptive, exploratory, bayesian basket trial
2025-521371-31-00Sepsis
Assistance Publique Hopitaux De Paris
Bacterial Infections and Mycoses
France
24/11/2025
Phase II
ALaDIN - Use of low doses of interleukin-2 in autism spectrum disorders
2025-522841-23-00Autism Spectrum disorder ASD
Assistance Publique Hopitaux De Paris
Mental Disorders
France
17/11/2025
Phase II
BASECOVID - Bevacizumab in post-acute sequelae of COVID-19 : Efficacy and Safety (Pilot Study)
2024-520308-24-00Adult patients with persistent dyspnea more than 3 months a…
Assistance Publique Hopitaux De Paris
Virus Diseases
France
24/10/2025
Phase II
CBD-SIB - Efficacy of cannabidiol in the management of Self-Injurious Behavior in children and adolescents with severe neurodevelopmental disorders
2025-521161-27-00Children and adolescents with severe neurodevelopmental dis…
Assistance Publique Hopitaux De Paris
Behavior and Behavior Mechanisms
France
07/10/2025
Phase II
CRYOBI study - A multicenter phase 2 single-arm proof-of-concept trial assessing the efficacy and safety of Obinutuzumab in the treatment of non-infectious active cryoglobulinemia vasculitis refractory or intolerant to Rituximab
2023-508930-33-00Non-infectious active cryoglobulinemia vasculitis who are e…
Assistance Publique Hopitaux De Paris
Immune System Diseases
France
02/10/2025
Rows per page Showing 1–17 of 17
1
Cite this view

Priya Life Science (2026). EU Clinical Trials Register (CTIS), filtered. Derived from the EMA Clinical Trials Information System. Retrieved 20 September 2026. https://priyalifescience.com/clinical-trials-europe

Query this register directly
GET /api/export.php?register=trials-eu&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. Looking for Irish sites? See the Ireland, UK or USA registers. For approved medicines, see the EMA Approvals Tracker.